Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine131-tositumomab for previously treated, rituximab-exposed, indolent non-Hodgkin lymphoma

2014 ◽  
Vol 55 (12) ◽  
pp. 2754-2760 ◽  
Author(s):  
Harold J. Olney ◽  
Marni A. Freeman ◽  
Douglas A. Stewart ◽  
Joy E. Mangel ◽  
Darrell J. White ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prospective Study ◽  
Hodgkin Lymphoma ◽  
Progression Free Survival ◽  
Free Survival ◽  
Non Hodgkin Lymphoma ◽  
Previously Treated

Poster: ABCL-238: Determinants of Quality of Life in Non-Hodgkin Lymphoma Patients: Moldavian Experiences

2021 ◽  
Vol 21 ◽  
pp. S243
Author(s):  
Buruiana Sanda ◽  
Maria Robu ◽  
Victor Tomacinschi ◽  
Aliona Golub ◽  
Cristina Catan ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hodgkin Lymphoma ◽  
Non Hodgkin Lymphoma

scholarly journals RBTT-04. DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS

2018 ◽  
Vol 20 (suppl_6) ◽  
pp. vi234-vi235
Author(s):  
Kim Edelstein ◽  
Kristin Campbell ◽  
Lori Bernstein ◽  
Ilyse Lax ◽  
Felicity Backhouse ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Progression Free Survival ◽  
Free Survival

scholarly journals A Canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma

2017 ◽  
Vol 24 (1) ◽  
pp. 33 ◽  
Author(s):  
D. MacDonald ◽  
T. Crosbie ◽  
A. Christofides ◽  
W. Assaily ◽  
J. Wiernikowski
Keyword(s):  
Quality Of Life ◽  
Health Care ◽  
Hodgkin Lymphoma ◽  
Health Care Providers ◽  
Subcutaneous Administration ◽  
Fixed Dose ◽  
Care Providers ◽  
Health Care Resources ◽  
Non Hodgkin Lymphoma

Rituximab is widely used for the treatment of non-Hodgkin lymphoma, being a key component in most therapeutic regimens. Administration of the intravenous (IV) formulation is lengthy and places a significant burden on health care resources and patient quality of life. A subcutaneous (sc) formulation that provides a fixed dose of rituximab is being examined in a number of studies. Results indicate that the pharmacokinetics are noninferior and response rates are comparable to those obtained with the IV formulation. Moreover, the sc formulation is preferred by patients and health care providers and reduces administration and chair time. Additional advantages include a lesser potential for dosing errors, shorter preparation time, reduced drug wastage, and fewer infusion-related reactions. Despite the success of the sc formulation, correct administration is needed to reduce administration-related reactions. By using a careful procedure, the sc formulation can be given safely and effectively, potentially reducing the burden on health care resources and improving quality of life for patients.

Quality of life (QOL) as a predictor of survival in aggressive non-Hodgkin lymphoma (NHL).

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 8059-8059
Author(s):  
C. A. Thompson ◽  
M. J. Maurer ◽  
C. Allmer ◽  
S. L. Slager ◽  
K. J. Yost ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hodgkin Lymphoma ◽  
Non Hodgkin Lymphoma

scholarly journals Physical Activity and Quality of Life of Adult Survivors of Non-Hodgkin Lymphoma

2016 ◽  
Vol 31 (4) ◽  
pp. 551-558
Author(s):  
Yoshiko ARATAKE ◽  
Hiroko KOMATSU ◽  
Yuko OGUMA ◽  
Jo ISHIZAWA ◽  
Takehiko MORI ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Physical Activity ◽  
Hodgkin Lymphoma ◽  
Adult Survivors ◽  
Non Hodgkin Lymphoma
Sign in / Sign up

Export Citation Format

Share Document